VOL. XCIV, NO. 247
★ MOAT STOCKS & COMPETITIVE ADVANTAGES ★
PRICE: 5 CENTS
Tuesday, December 23, 2025
Thermo Fisher Scientific Inc.
TMO · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Thermo Fisher Scientific is a diversified life-sciences tools and services company with four reporting segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Its moat is driven by breadth of portfolio and brands, a large global commercial footprint (direct sales, e-commerce, and technical specialists), and recurring consumables and services tied to customer workflows and instrument installed bases. Laboratory Products and Biopharma Services provides scale through lab distribution plus outsourced pharma services, while Life Sciences Solutions tends to contribute an outsized share of segment income relative to revenue.
Primary segment
Laboratory Products and Biopharma Services
Market structure
Competitive
Market share
—
HHI: —
Coverage
4 segments · 7 tags
Updated 2025-12-22
Segments
Life Sciences Solutions
Life science research tools and bioprocessing consumables/instruments
Revenue
19%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Analytical Instruments
Analytical instruments (chromatography, mass spectrometry, electron microscopy) with consumables and services
Revenue
17%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Specialty Diagnostics
Specialty diagnostics (immunodiagnostics, microbiology, transplant diagnostics) and related consumables
Revenue
10.4%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Laboratory Products and Biopharma Services
Laboratory supplies distribution/market channel plus outsourced biopharma services (CDMO/CRO)
Revenue
53.6%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Moat Claims
Life Sciences Solutions
Life science research tools and bioprocessing consumables/instruments
Revenue_share and operating_profit_share computed from FY2024 10-K Note 11 Business Segment Information (filed 2025-02-20): https://www.sec.gov/Archives/edgar/data/97745/000009774525000010/tmo-20241231.htm
Installed Base Consumables
Demand
Installed Base Consumables
Strength: 4/5 · Durability: durable · Confidence: 4/5 · 2 evidence
Reagents/consumables attached to instruments and single-use bioproduction workflows create recurring pull-through once adopted and validated in lab processes.
Erosion risks
- Protocol standardization on open reagents reduces consumables differentiation
- Pricing pressure as competitors bundle similar bioprocessing consumables
- Funding cycles (NIH/academia) and biopharma demand volatility
Leading indicators
- Consumables mix vs instruments mix
- Attach rate of proprietary reagents/kits to installed base
- Gross margin trend in Life Sciences Solutions
Counterarguments
- Many workflows can be multi-sourced (reagents and plastics) with limited switching cost
- Large customers can negotiate aggressively using dual sourcing
Format Lock In
Demand
Format Lock In
Strength: 3/5 · Durability: medium · Confidence: 3/5 · 1 evidence
Genetic science platforms often pair instruments with related reagents, which can create assay format/workflow dependence over time.
Erosion risks
- Open-source methods and third-party reagents reduce platform dependence
- New modalities can bypass incumbent instrument/reagent formats
Leading indicators
- Share of segment revenue from proprietary reagents/kits
- Installed base growth/decline for key platforms
Counterarguments
- Labs often run mixed fleets and use cross-compatible consumables where possible
Brand Trust
Demand
Brand Trust
Strength: 4/5 · Durability: durable · Confidence: 4/5 · 1 evidence
Well-known brands (e.g., Thermo Scientific, Applied Biosystems, Invitrogen) reduce adoption friction and support enterprise procurement.
Erosion risks
- Product recalls/quality issues could damage brand trust
- Share shifts to newer niche innovators in fast-moving categories
Leading indicators
- Customer satisfaction/NPS trends
- Warranty/field failure rates and major recall events
Counterarguments
- Instruments are often evaluated on performance/total cost rather than brand alone
Analytical Instruments
Analytical instruments (chromatography, mass spectrometry, electron microscopy) with consumables and services
Revenue_share and operating_profit_share computed from FY2024 10-K Note 11 Business Segment Information (filed 2025-02-20): https://www.sec.gov/Archives/edgar/data/97745/000009774525000010/tmo-20241231.htm
Installed Base Consumables
Demand
Installed Base Consumables
Strength: 4/5 · Durability: durable · Confidence: 4/5 · 1 evidence
Large installed base of instruments supports recurring revenue from consumables, software, and service contracts.
Erosion risks
- Third-party consumables and service providers reduce capture of aftermarket revenue
- Technology shifts can shorten instrument replacement cycles
Leading indicators
- Service and consumables revenue as a % of Analytical Instruments revenue
- Service contract renewal rates
Counterarguments
- Customers can standardize on open consumables and multi-vendor service where feasible
Service Field Network
Supply
Service Field Network
Strength: 3/5 · Durability: medium · Confidence: 4/5 · 2 evidence
Dense global sales/service presence and technical specialists improve uptime and reduce switching in mission-critical lab environments.
Erosion risks
- Remote/AI diagnostics and third-party service networks reduce differentiation
- Labor costs and retention challenges for field engineers
Leading indicators
- Field service response-time and uptime metrics (if disclosed)
- Service gross margin trend
Counterarguments
- Competitors also maintain strong global service teams; differentiation may be modest
Specialty Diagnostics
Specialty diagnostics (immunodiagnostics, microbiology, transplant diagnostics) and related consumables
Revenue_share and operating_profit_share computed from FY2024 10-K Note 11 Business Segment Information (filed 2025-02-20): https://www.sec.gov/Archives/edgar/data/97745/000009774525000010/tmo-20241231.htm
Installed Base Consumables
Demand
Installed Base Consumables
Strength: 4/5 · Durability: durable · Confidence: 4/5 · 1 evidence
Diagnostics menu and instrument placement drive recurring pull-through of reagents, culture media, and test kits.
Erosion risks
- Hospital and lab consolidation increases buyer bargaining power
- Rapid innovation cycles can displace assay menus
- Potential portfolio changes (divestitures) can alter scale advantages
Leading indicators
- Installed base and reagent pull-through growth (if disclosed)
- Regulatory warning letters or major quality events
Counterarguments
- Large IVD players can match menu breadth and compete aggressively on price
Regulated Standards Pipe
Legal
Regulated Standards Pipe
Strength: 3/5 · Durability: durable · Confidence: 4/5 · 1 evidence
Complex regulatory and compliance requirements raise barriers for new entrants and slow competitive imitation in regulated diagnostics workflows.
Erosion risks
- Regulatory harmonization or faster approval pathways reduce barriers
- Compliance costs rise (quality systems, audits), pressuring margins
Leading indicators
- Time-to-approval for new assays/instruments
- Changes in FDA/IVDR/other regulatory regimes
Counterarguments
- Incumbent competitors already have strong regulatory capabilities; regulation may not be a differentiator
Laboratory Products and Biopharma Services
Laboratory supplies distribution/market channel plus outsourced biopharma services (CDMO/CRO)
Revenue_share and operating_profit_share computed from FY2024 10-K Note 11 Business Segment Information (filed 2025-02-20): https://www.sec.gov/Archives/edgar/data/97745/000009774525000010/tmo-20241231.htm
Distribution Control
Supply
Distribution Control
Strength: 4/5 · Durability: durable · Confidence: 4/5 · 2 evidence
Large lab distribution platform with broad catalog and services creates one-stop procurement convenience and embeds Thermo Fisher in customer supply chains.
Erosion risks
- Disintermediation via manufacturer-direct and e-procurement marketplaces
- Large customers shifting to multi-vendor frameworks to force price competition
Leading indicators
- E-commerce penetration and digital procurement adoption
- Gross margin trend in Laboratory Products and Biopharma Services
Counterarguments
- Competitors with scale (e.g., Avantor/VWR) can offer similar catalog breadth and logistics
Procurement Inertia
Demand
Procurement Inertia
Strength: 3/5 · Durability: medium · Confidence: 4/5 · 2 evidence
Product standardization and supply-chain-management services reduce procurement friction, increasing switching costs for enterprise customers.
Erosion risks
- Procurement organizations push periodic re-bids and standardize across vendors
- Digital marketplaces lower switching friction
Leading indicators
- Customer retention/renewal of supply agreements (if disclosed)
- Share of wallet with enterprise accounts
Counterarguments
- Switching distributors can be managed during contract re-bids; inertia may be limited
Capacity Moat
Supply
Capacity Moat
Strength: 3/5 · Durability: medium · Confidence: 3/5 · 2 evidence
Biopharma services require specialized global capacity and integrated capabilities (development, manufacturing, clinical services), which take time and capital to replicate.
Erosion risks
- New CDMO/CRO capacity additions compress pricing and reduce scarcity
- Project cancellations or funding slowdowns reduce utilization
Leading indicators
- Capacity utilization and backlog trends (if disclosed)
- New facility expansions and capex intensity
Counterarguments
- CDMO/CRO markets are fragmented; capable competitors can scale with capital and hiring
Evidence
...we provide an extensive portfolio of reagents, instruments and consumables used in biological and medical research...
Supports recurring consumables + instrument ecosystem in the segment.
...a suite of single-use solutions spanning the biologics workflow.
Single-use bioprocessing products are structurally consumable/recurring.
Our genetic sciences business combines a wide variety of instruments and related reagents...
Explicit linkage between instruments and reagents supports format/workflow lock-in.
...through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen...
Brand strength is positioned by the company as a differentiator in go-to-market.
...we provide a broad offering of instruments and the supporting consumables, software and services...
Directly describes the instrument + consumables/software/services model.
Showing 5 of 15 sources.
Risks & Indicators
Erosion risks
- Protocol standardization on open reagents reduces consumables differentiation
- Pricing pressure as competitors bundle similar bioprocessing consumables
- Funding cycles (NIH/academia) and biopharma demand volatility
- Open-source methods and third-party reagents reduce platform dependence
- New modalities can bypass incumbent instrument/reagent formats
- Product recalls/quality issues could damage brand trust
Leading indicators
- Consumables mix vs instruments mix
- Attach rate of proprietary reagents/kits to installed base
- Gross margin trend in Life Sciences Solutions
- Share of segment revenue from proprietary reagents/kits
- Installed base growth/decline for key platforms
- Customer satisfaction/NPS trends
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.